Treatment for RR/MDR tuberculosis: a comparative analysis of programmatic outcome indicators between Buenaventura and other municipalities of Valle del Cauca-Colombia
Abstract
Introduction. Proper management of multi-resistant tuberculosis is a prioritized strategy for the tuberculosis control worldwide.
Objective. To evaluate differences with respect to demographic, clinical characteristics and programmatic indicators of the cohort of patients with confirmed diagnosis of RR/MDR TB from Buenaventura, compared to a cohort of the other municipalities from the state of Valle del Cauca – Colombia, 2013-2016.
Materials and methods. Analytical cohort study that compared records of >15 years of age with RR/MDR TB from Buenaventura tuberculosis program (uses para-aminosalicylic acid -PAS) versus the other municipalities of Valle del Cauca (do not uses PAS).
Results. 99 cases were recorded, the median age was 40 years (IQR 26-53); in Buenaventura 56% were women, in the other municipalities men predominated 67%; 95% had health insurance. The most common comorbidity was diabetes (14%). Adverse Reactions to Antituberculosis Medications (AFR) in Buenaventura were 1.3 times higher than in the other municipalities (OR 2.3 95% CI 0.9933-5.568; p=0.04). In Buenaventura, 5% of the cases died compared to the 15% reported in the other municipalities. There were no treatment failures in Buenaventura, but 35% loss to follow-up was reported. Treatment success was higher in Buenaventura, with 56%.
Conclusion. A strengthened program in Buenaventura presented better programmatic results than the other municipalities of Valle del Cauca. Access to molecular tests, the availability of shortened treatments and continuous monitoring to identify RAFAS is a path forward for all other control programs.
Downloads
Some similar items:
- John-Leonardo Torres-Castiblanco, Jorge Alberto Carrillo, Daniel Hincapié-Urrego, Adriana Rojas-Villarraga, Tuberculosis in the era of anti-TNF-alpha therapy: Why does the risk still exist? , Biomedica: Vol. 38 No. 1 (2018)
- Claudia Llerena, Angie Zabaleta, Angélica Valbuena, Martha Murcia, Prevalence of Mycobacterium tuberculosis resistance to quinolones and injectables in Colombia, 2012-2013 , Biomedica: Vol. 37 No. 1 (2017)
- Leandro Galvis, Ángel Y. Sánchez, Leonardo F. Jurado, Martha I. Murcia, Tuberculosis associated with tumor necrosis factor-α antagonists, case description and analysis of reported cases in Colombia , Biomedica: Vol. 38 No. 1 (2018)
- Angie Zabaleta, Claudia Llerena, Extensively resistant tuberculosis, Colombia, 2006-2016 , Biomedica: Vol. 39 No. 4 (2019)
- Julio César Martínez, Claudia Llerena, Yanely Angélica Valbuena, The Importance of investigating Mycobacterium bovis in clinical samples of human origin , Biomedica: Vol. 39 No. Sp. 1 (2019): Suplemento 1, Microbiología médica, mayo
- Juan Gabriel Bueno-Sánchez, Jairo René Martínez-Morales, Elena E. Stashenko, Wellman Ribón, Anti-tubercular activity of eleven aromatic and medicinal plants occurring in Colombia , Biomedica: Vol. 29 No. 1 (2009)
- Sonia Isabel Cuervo, Diego Andrés Bonilla, Martha Isabel Murcia, Johana Hernández, Julio César Gómez, Tuberculosis of the breast , Biomedica: Vol. 33 No. 1 (2013)
- Diana Castaño, Mauricio Rojas, Alterations in recruitment and activation of Rab proteins during mycobacterial infection , Biomedica: Vol. 30 No. 2 (2010)
- Luis F. García, Luis F. Barrera, Perspectives for new anti-tuberculous vaccines in the post-genomic era. , Biomedica: Vol. 24 (2004): Suplemento 1
- Alvaro Javier Idrovo, Historical, social and epidemiological roots of tuberculosis in Bogotá, Colombia. , Biomedica: Vol. 24 No. 4 (2004)
Copyright (c) 2024 Biomedica
This work is licensed under a Creative Commons Attribution 4.0 International License.
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |